Immunotherapy Program at Northside
Northside Hospital Cancer Institute has been named a top 2026 50 US hospital for cancer care by US News & World Report and ranks in the top 6% of all US cancer programs.
All four Northside hospitals received a High Performing designation for the treatment of multiple myeloma, leukemia, and non-Hodgkin lymphoma patients.
Northside Hospital’s Immunotherapy Program is a nationally recognized CAR T-cell, TIL and IEC treatment center.
Northside Hospital’s Immunotherapy: Program FACTS:
Within five to ten business days of the initial referral, patients will be evaluated by Northside Hospital’s immunotherapy physicians.
Dedicated cellular therapy clinical coordinators will organize and coordinate care from new patient consultation through treatment follow-up.
With onsite apheresis capabilities at Atlanta Blood Services, our team is able to schedule T-cell apheresis within days of a new patient's consultation.
A dedicated financial team that is able to expeditiously obtain financial approval for all immunotherapy treatments, including CAR T-cell, TILs, and IEC products.
Continuous communication with referring hematologists, oncologists, and rheumatologists to ensure bridging therapy is initiated if necessary.
Please visit immunotherapy clinical trials for a listing of leukemia, multiple myeloma, diffuse large B-cell lymphoma, lupus, and other various disease-specific immunotherapy trials.
WSB’s radio program, Doctors on Call, interview
On April 12, 2026, WSB’s Doctors on Call radio host, Belinda Skelton, interviewed Dr. Melhem Solh, a physician at The Blood & Marrow Transplant Group of Georgia and the medical director of Northside’s Cellular Therapy Program, who described treatment updates and how our program provides leading-edge therapies for our patients.
Available Commercial CAR T-cell, TIL, and IEC Products
B-CELL MALIGNANCIES
Northside is an authorized treatment center for the following types of CAR T-cell therapies to treat B-cell malignancies:
BREYANZI™ For adult patients with:
Relapsed or refractory (R/R) large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, are refractory to first-line chemoimmunotherapy, relapsed within 12 months of first-line chemoimmunotherapy, or after two or more lines of systemic therapy.
Relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy.
Relapsed or refractory (R/R) mantle cell lymphoma after two or more lines of systemic therapy, including a BTK inhibitor.
Relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), after two or more lines of systemic therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Relapsed or refractory (R/R) marginal zone lymphoma who have received at least two prior lines of systemic therapy.
KYMRIAH® For adult patients with:
Relapsed or refractory (R/R) large B-cell lymphoma, including DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, and after two or more lines of systemic therapy.
Relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy.
TECARTUS™ For adult patients with:
Relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
YESCARTA® For adult patients with:
Relapsed or refractory (R/R) large B-cell lymphoma, including primary central nervous system lymphoma, refractory to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy.
Relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy.
Relapsed or refractory (R/R) aggressive large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, DLBCL arising from follicular lymphoma (FL), and after two or more lines of systemic therapy.
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Northside is an authorized treatment center for the following types of CAR T-cell therapies to treat acute lymphoblastic leukemia (ALL):
AUCATZYL®: For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
CAR T product is given in 2 doses - the treatment regimen consists of a split dose infusion to be administered on Day 1 and Day 10 (± 2 days) (2.1). Dose to be administered is determined by the patient's bone marrow blast assessment.
KYMRIAH®: For patients up to 25 years old with B-cell precursor acute lymphoblastic leukemia (ALL) where ALL is refractory or in a second or later relapse.
TECARTUS™: For adult patients with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL)
MULTIPLE MYELOMA
Northside is an authorized treatment center for the following types of CAR T-cell therapies to treat multiple myeloma:
ABECMA®: For adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
*Newly diagnosed high-risk MM patients (R-ISS III) should be referred soon after initial diagnosis to determine CAR-T eligibility. Please contact the Hematological Malignancy Coordinator at BloodCancerCoord@northside.com, Office: 470-945-8745 or Fax: 404-255-1939.CARVYKTI®: For adult patients with relapsed or refractory (R/R) multiple myeloma after one (1) or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and are refractory to lenalidomide.
*Newly diagnosed high-risk MM patients (R-ISS III) should be referred soon after initial diagnosis to determine CAR-T eligibility. Please contact the Hematological Malignancy Coordinator at BloodCancerCoord@northside.com, Office: 470-945-8745 or Fax: 404-255-1939.
Melanoma: TIL Therapy
Amtagvi (lifileucel) is now available as a second-line therapy for patients with unresectable or metastatic melanoma. Northside’s Immunotherapy Program is the FIRST approved TIL treatment center in Georgia.>18 years of age with unresectable or metastatic melanoma
Must have progressed on at least 1 previous systemic therapy, including a PD-L1 antibody, and if they had BRAF V600E mutation-positive disease, a BRAF or BRAF/MEK inhibitor.
At least 1 resectable lesion
For more information on TIL Therapy, click here.
